rdf-syntax-grammar
mods:
  schema location: http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-2.xsd
  title info:
    title: Patent strategy in pharmaceutical industry
    sub title: are additional patents valuable?
  name:
    name part: Donghi, Monica.
    role:
      role term: creator
  name:
    name part: JSTOR (Organization)
  type of resource: text
  genre: bibliography
  genre: Electronic books.
  genre: Patents.
  origin info:
    place:
      place term: gw
    date issued: 2014
    edition: 1. Aufl.
    issuance: monographic
  language:
    language term: eng
  physical description:
    form: remote
    extent: 1 online resource (85 pages).
  abstract: Dieses Buch untersucht die Lifecycle-Management-Strategien, die von Pharma-Unternehmen eingesetzt werden, um den Wert ihres Produktportfolios zu maximieren. Solche Strategien werden manchmal von Generika-Unternehmen als "evergreening" bezeichnet. Die Analyse erfolgt anhand zwei zufällig ausgewählter "Blockbuster"--Medikamente, Taxotere und Xalatan und konzentriert sich auf zwei dieser Strategien, nämlich die Produktverbesserung und die Produktlinienerweiterung. Reihe Munich Intellectual Property Law Center - MIPLC - Band 20.
  table of contents: Acronyms and Abbreviations; I. Introduction; II. Background; A. Pharmaceutical Industry -- The Development of a New Drug.; B. New Drug Approval Regulations; C. Generic Drugs Approval.; III. Case Studies-Facts; A. Taxotere; 1. General; 2. Patent Portfolio; a) Process; b) Formulation; c) Combination Therapy; d) New Uses; e) Derivatives; 3. Use of Procedural Provisions: Supplementary Protection Certificates (SPCs)/Patent Term Extension; 4. Conclusion; B. Xalatan; 1. General; 2. Patent Portfolio; a) Process; b) Formulation; c) Combination Therapy; d) New Uses; e) Delivery Devices.
  table of contents: F) Packaged Product3. Use of Procedural Provisions; a) Divisional of Basic Patent; b) Supplementary Protection; 4. Conclusion; IV. Discussion; A. Lifecycle Management: Criticism and Supports; B. Further Filing Strategy: Commercial Value; 1. Innovation Tracks; a) Formulations; b) Combinations; c) Process; d) New Uses; e) Delivery Devices; 2. Xalatan SPC Request: a Case for Competition Law?; C. Patent Strategy and Innovation; D. Summary: Taxotere v Xalatan; E. Conclusion and Suggestions; V. Final Remarks; List of works cited; Periodical Materials in English; Periodical Material in German.
  table of contents: Non Periodical MaterialTable of books; Table of Cases; European Union; EPO Board of Appeal; France; Germany; Italy; United Kingdom; United States; Statutes; Speeches and Reports; Press release; Others.
  note: Monica Donghi.
  note: Electronic resource.
  note: Includes bibliographical references.
  subject:
    topic: Drugs
    genre: Patents
  subject:
    topic: Drugs
  subject:
    topic: LAW / Commercial / General
  classification: K1519.D78 D66 2014
  classification: 346.04/86
  related item:
    title info:
      title: Patent Strategy in Pharmaceutical Industry: Are additional patents valuable?
    name:
      name part: Donghi, Monica.
    origin info:
      publisher: Baden-Baden : Nomos Verlagsgesellschaft, ©2014
  related item:
    title info:
      title: MIPLC studies ; v. 20
  identifier: 9783845251288
  identifier: 384525128X
  identifier: 22573/ctv931rkz JSTOR
  identifier: http://proxy.library.tamu.edu/login
  record info:
    record content source: YDXCP
    record creation date: 140315
    record change date: 20260728172704.3
    record identifier: in00004018301
    language of cataloging:
      language term: eng